Clinical trial

Olinvacimab With Pembrolizumab in Patients With mTNBC

NCT04986852

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2021-09-30

PhasePHASE2

Study timeline

Study start (actual)2021-09-30Date precision: day

Registry last updated2025-12-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Triple-Negative Breast Cancerunresolved

Interventions

OlinvacimabDRUG

Sponsors & collaborators

PharmAbcinelead sponsor

Merck Sharp & Dohme LLCcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04986852 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.